文献速递类风湿关节炎

体重指数与RA患者TNFα抑制剂治疗生存的长期随访:METEOR注册研究

Body mass index and treatment survival in patients with RA starting treatment with TNFα-inhibitors: long-term follow-up in the real-life METEOR registry.
PubMed 文献 · RMD Open · 2020-01-01

基于METEOR真实世界注册研究5230例起始TNFi治疗的RA患者,按BMI分六组比较治疗生存。BMI II/III级肥胖及体重过低者TNFi生存显著短于正常体重,未发现疼痛是主要决定因素。

要点

  • BMI II级(HR 1.28)和III级(HR 1.67)肥胖及体重过低(HR 1.30)者TNFi生存显著短于正常体重。
  • 体重过低对英夫利西单抗影响最强(HR 1.82);超重对英夫利西单抗和依那西普影响较强。
  • 未发现报告疼痛对BMI与TNFi生存关联有显著效应修饰。

核心结论

  • 体重过低和超重/肥胖的RA患者均较正常体重者更早停用TNFi治疗。
  • 未发现报告疼痛是TNFi生存的主要决定因素。
  • 个体患者TNFi生存的决定因素仍不确定。

研究设计与样本

  • METEOR国际真实世界纵向注册研究,纳入5230例起始任何TNFi治疗的RA患者。
  • 按BMI分六组:体重过低3.7%(<18.5 kg/m2)、正常体重46%(18.5-25 kg/m2)、超重32%(25-30 kg/m2)、肥胖I级13%(30-35 kg/m2)、肥胖II级3.4%(35-40 kg/m2)、肥胖III级1.6%(>40 kg/m2)。
  • 采用Kaplan-Meier曲线和Cox回归比较各组治疗时间,校正潜在混杂因素,随访删失于5000天。

主要发现

  • 肥胖II级(HR 1.28,95%CI 1.06-1.54)和III级(HR 1.67,95%CI 1.29-2.18)及体重过低(HR 1.30,95%CI 1.07-1.58)者TNFi生存显著短于正常体重。
  • 体重过低对英夫利西单抗影响最强(HR 1.82,95%CI 1.20-2.76)。
  • 超重对英夫利西单抗影响:II级HR 1.49(95%CI 0.98-2.26),III级HR 1.46(95%CI 0.79-2.71);对依那西普:II级HR 1.27(95%CI 0.98-1.65),III级HR 1.79(95%CI 1.25-2.55)。
  • 未发现报告疼痛对BMI与TNFi生存关联有显著效应修饰。

临床怎么用

  • 临床起始TNFi治疗前应关注RA患者BMI,体重过低及肥胖II/III级者可能更早停药。
  • 对体重过低或严重肥胖患者,选择TNFi时需考虑治疗生存可能较短。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To study whether there is an association between body mass index (BMI) category and survival of various tumour necrosis factor inhibitors (TNFi) in rheumatoid arthritis (RA) patients in a real-life longitudinal international registry. METHODS: Data from 5230 patients with RA starting treatment with any TNFi were selected from the METEOR registry. Patients were divided into six BMI categories: 3.7% underweight, BMI<18.5 kg/m2; 46% normal weight, BMI 18.5-25 kg/m2; 32% pre-obesity, BMI 25-30 kg/m2; 13% obesity class I, BMI 30-35 kg/m2; 3.4% obesity class II, BMI 35-40 kg/m2; and 1.6% obesity class III, BMI >40 kg/m2. Time on treatment in the different BMI categories was compared for all TNFi combined and for the infliximab, adalimumab and etanercept separately, using Kaplan-Meier curves and Cox regression analyses. Cox regression analyses were adjusted for potential confounders, with follow-up censored at 5000 days. RESULTS: Patients in obesity class II (HR 1.28, 95% CI 1.06 to 1.54) and III (HR 1.67, 95% CI 1.29 to 2.18) and underweight patients (HR 1.30, 95% CI 1.07 to 1.58) showed statistically significantly shorter TNFi survival than normal weight patients. The effect in underweight patients was strongest for infliximab (HR 1.82, 95% CI 1.20 to 2.76), the effect in overweight patients was strongest for infliximab (category II (HR 1.49, 95% CI 0.98 to 2.26); category III (HR 1.46, 95% CI 0.79 to 2.71)) and etanercept (category II (HR 1.27 95% CI 0.98 to 1.65); category III (HR 1.79, 95% CI 1.25 to 2.55)). No significant effect modification from reported pain was found. CONCLUSION: Both underweight and overweight patients discontinued TNFi treatment earlier than normal weight patients, without evidence of reported pain as the main determinant. It remains uncertain what determines TNFi survival in individual patients.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Bergstra SA, Allaart CF, Vega-Morales D, et al. Body mass index and treatment survival in patients with RA starting treatment with TNFα-inhibitors: long-term follow-up in the real-life METEOR registry. RMD Open. 2020. PMID: 32506054. doi:10.1136/rmdopen-2020-001203

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。